Sample analysis from the Janssen trial was due to be completed mid year anytime now which means results are not be too far away June/July. Likely to be very significant for PIQ.
Not rushing commercialisation deals makes sense until the uptake of the test gains traction as this would add significant value to any deal. Once a deal is locked in you can't renegotiate. For the sake of a few months it's best to give KOL's opportunity to engage, may be taking longer than anticipated but could prove more fruitful in the end.
Sample analysis from the Janssen trial was due to be completed...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $49.05M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 29.0¢ | $101.2K | 339.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12211 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 30451 | 2 |
View Market Depth
| Last trade - 12.03pm 26/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |